Commerce & Finance Law Offices and O’ Melveny & Myers have advised China biotech company Akeso on its $312 million IPO in Hong Kong, with Tian Yuan Law Firm and Davis Polk & Wardwell acting for the joint sponsors.
According to Commerce & Finance, Akeso is the sixteenth unprofitable biotech company to be listed on the Hong Kong Stock Exchange, and this is by far the biggest Hong Kong IPO in 2020.
Founded in 2012, Akeso is a clinical-stage biopharmaceutical company committed to in-house discovery, development and commercialisation of first-in-class and best-in-class therapies. It dedicates to address global unmet medical needs in oncology, immunology and other therapeutic areas.
The Davis Polk team was led by partners Li He and Yang Chu.